Biorce Raises €5M to Streamline Clinical Trials Using AI

3 min read
Co-founder of JustAINews
Share
Key Points
  • Biorce raises €5M from Norrsken VC, following earlier investments from YZR Capital and Mustard Seed Maze.
  • The new funds will support Biorce’s US expansion, product development, and growth of its engineering and sales teams.
  • Biorce’s AI platform Jarvis addresses clinical trial inefficiencies, significantly speeding up new treatments for patients.
Norrsken VC and Biorce
Credits: Norrsken VC official website

Barcelona-based healthtech startup Biorce has raised €5 million in new funding from Norrsken VC, just seven months after securing €3.5 million from YZR Capital and Mustard Seed Maze in a seed round. The latest funding will fuel the company's expansion into the US and support the growth of its engineering and sales teams. Biorce is also focusing on accelerating product development, with ambitions to reach eight-digit revenue figures.

"Biorce is exactly the kind of pioneering company we’re here to back. They’re combining deep sector expertise with cutting-edge AI to solve what truly matters. Their platform has the potential to radically reduce both the time and cost of bringing new treatments to market, unlocking huge value for pharma and, more importantly, faster access to life-saving therapies for patients."

Norrsken VC's General Partner, Tove Larsson

Solving Critical Delays in Clinical Trials

Clinical trials are essential but notoriously slow and costly. Currently, about 70% of trials experience delays even before starting, and nearly 60% undergo expensive changes mid-process. Each amendment can add several months and hundreds of thousands of dollars in expenses. Beyond the financial impact, these delays have severe consequences for patients waiting for potentially life-saving treatments.

"We’re tackling the root causes of delay and inefficiency in clinical trials: issues that cost time, money, and ultimately lives. Our solution cuts through complexity, shortens timelines, and improves outcomes for patients. When my father was diagnosed with cancer, we were lucky to find a clinical trial that extended his life by ten months, but that kind of access is far from the norm. Our goal is to make clinical trials faster and cheaper so that we can get those opportunities to all patients and not just those lucky enough to join a trial."

Pedro Coelho, founder and CEO of Biorce

Expanding Market Presence and Development

With the new investment, Biorce aims to significantly expand its presence in the US market. The funds will also help scale the company's technical and commercial capabilities. By growing its engineering and sales teams, Biorce plans to strengthen its platform, making clinical trials faster, more efficient, and accessible to a wider patient population.

Biorce is particularly focused on refining its AI-native platform, Jarvis, which streamlines clinical trial processes from patient recruitment and protocol design to selecting trial sites. Leveraging data from over 530,000 studies, Jarvis enables trial teams to make better decisions upfront, preventing costly and time-consuming errors later.

About Biorce: Transforming Clinical Trials with AI

Founded by Pedro Coelho and a dedicated team including Clara, Diogo, and Jose, Biorce is dedicated to transforming the clinical trial landscape. Based in Barcelona, the startup combines healthcare expertise with advanced AI technology to simplify and optimize the trial process, dramatically reducing time-to-market for new treatments by up to 50%.

What sets Biorce apart is its comprehensive solution that directly addresses the inefficiencies in clinical trial operations. By providing clear insights and smarter decision-making tools, Biorce significantly reduces delays, lowering overall costs, and ensuring quicker patient access to critical therapies.

Investment and Growth Momentum

Following this recent €5 million investment from Norrsken VC, Biorce has demonstrated impressive momentum since its previous seed round led by YZR Capital and Mustard Seed Maze. This rapid growth highlights investor confidence in Biorce's potential to substantially impact the healthcare industry by improving clinical trial efficiency and patient outcomes.

Subscribe to JustAINews!

Get the industry's biggest AI news straight to your inbox.
Subscribe

Related posts

© Copyright 2025 - Just AI News - All Rights Reserved
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram